IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	PATENT APPLICATION
Inventor(s): Filvaroff)	Art Unit: 1646
Application No.: 10/617,573)	Art Onit: 1040
Filed: July 11, 2003)	Examiner: Jiang, Dong
Title Pharmaceutical compositions, kits and therapeuti uses of antagonist antibodies to IL-17E	ic)	

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop ____ Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and foreign patent, except for pending U.S. applications and issued U.S. patents, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP 8609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):			
		(1)	It is being filed within 3 month continued prosecution applicat	s of the application filing date and is other than a ion under $\S 1.53(d)$
		(2)	It is being filed within 3 month	s of entry of a national stage
		(3)		date of the first Office Action on the merits
		(4)		ing of a first Office Action after the filing of a request er § 1.114.
\boxtimes	37 C.F.R. §1.97(e). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stag set forth in §1.491 in an international application; or (3) the mailing date of a first Office action or merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice o allowance under §1.311, then:			onths beyond the date of entry of the national stage as in; or (3) the mailing date of a first Office action on the
		a ccrtif	ication as specified in §1.97(e) i	s provided below; or
	\boxtimes		f \$180.00 as set forth in \$1.17(p) nt of other papers filed together	is authorized below, enclosed, or included with the with this statement.
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a fin action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fe			
	A.	a certif	ication as specified in §1.97(e) i	s completed below; and
	B.	a petiti herewi		uesting consideration of this statement is submitted
	C.		f \$130.00 as set forth in §1.17(i) nt of other papers filed together	(1) is authorized below, enclosed, or included with the with this statement.
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees o \$0.00 and charge any additional fees or credit any overpayment associated with this communication Deposit Account No. 50-4634 (Docket No. 123851-181748)			
				Respectfully submitted, GOODWIN PROCTER LLP
Dated:		Novemb	per 24, 2008	By: Jeffrey of Palkington, Reg. No. 58,381
	in Proct			,)
135 Commonwealth Drive Menlo Park, CA 94025				
(650) 752-3100				
Custon	ner No. 7	77845		